Nabla Bio vs Grok
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI antibody design platform targeting undruggable GPCRs and ion channels; $37M raised with $550M+ in AstraZeneca, BMS, and Takeda partnership milestones led by Radical Ventures.
About
Nabla Bio is a Harvard spinout biotech company using AI-driven generative protein design to develop antibodies against multipass membrane proteins — a class of drug targets including GPCRs (G protein-coupled receptors), ion channels, and transporters that are implicated in numerous diseases but have been historically undruggable with antibody therapies due to their complex 3D structure embedded in the cell membrane. A Y Combinator graduate, Nabla Bio raised $37 million total including a $26 million Series A led by Radical Ventures, and secured strategic collaborations with AstraZeneca, Bristol Myers Squibb, and Takeda worth $550 million+ in upfront and milestone payments plus royalties.
AI assistant by xAI (Elon Musk); Grok 3 topped reasoning benchmarks in Feb 2025; 1M+ paying subscribers in week one; real-time X post access; distributed via X Premium; xAI valued at $24B.
About
Grok is the AI assistant developed by xAI, Elon Musk's AI company founded in 2023, and distributed primarily through X (formerly Twitter). Grok launched in November 2023 as an X Premium perk, with the notable differentiator of real-time access to X posts and a less restricted, more direct conversational style. Grok 3, released in February 2025, achieved top scores on the AIME math reasoning benchmark and ARC-AGI test, briefly positioning xAI as a frontier model lab.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.